U.S. markets close in 5 hours 19 minutes
  • S&P 500

    -10.36 (-0.27%)
  • Dow 30

    +30.08 (+0.10%)
  • Nasdaq

    -177.57 (-1.40%)
  • Russell 2000

    -14.82 (-0.69%)
  • Crude Oil

    +1.81 (+2.84%)
  • Gold

    -2.50 (-0.15%)
  • Silver

    -0.23 (-0.89%)

    -0.0057 (-0.48%)
  • 10-Yr Bond

    +0.0060 (+0.39%)

    -0.0071 (-0.51%)

    +0.2070 (+0.19%)

    -2,169.74 (-4.31%)
  • CMC Crypto 200

    +19.52 (+2.07%)
  • FTSE 100

    +44.99 (+0.68%)
  • Nikkei 225

    -65.78 (-0.23%)

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Urges Allakos (ALLK) Investors with Losses to Contact Its Attorneys: 4 DAYS to APPLICATION DEADLINE

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

SAN FRANCISCO, CA / ACCESSWIRE / May 7, 2020 / Hagens Berman urges Allakos Inc. (NASDAQ:ALLK) investors who have suffered significant losses to submit their losses now. Only four days remain until the May 11, 2020 lead plaintiff deadline in a securities fraud class action that has been filed against the company and senior executives.

Class Period: Aug. 5, 2019 - Dec. 17, 2019

Lead Plaintiff Deadline: May 11, 2020

Visit: www.hbsslaw.com/investor-fraud/ALLK

Contact An Attorney Now: ALLK@hbsslaw.com


Allakos (ALLK) Securities Class Action:

The complaint alleges Defendants misled investors about the Company's Phase 2 clinical trial (the "ENIGMA Trial") for its flagship AK002 drug intended to treat patients with certain stomach diseases. Specifically, Defendants misrepresented and concealed that: (1) the ENIGMA Trial was poorly designed and not well-controlled; (2) Allakos had cherry-picked timeframes to engineer results for the ENIGMA Trial; (3) Allakos used superficial endpoints in the ENIGMA Trial relative to FDA guidance; (4) Allakos inaccurately reported the number of adverse incidents that occurred during the ENIGMA Trial; and (5) the Company failed to report other key data from the ENIGMA Trial.

According to the complaint, investors began to learn the truth on Dec. 18, 2019, when Seligman Investments published a scathing report entitled, "A Suspect Biotech with a Phase 2 Farce, Incredulous Trial Investigators, and Warning Signs of Potential Fraud," identifying several concerns with the ENIGMA Trial. Among other things, Seligman's 215-page report concluded that the ENIGMA Trial results "are compromised by 1) glaring omissions, 2) cherry-picked measures, and 3) statistical gimmicks and obfuscation." On this news, Allakos shares declined $13.25, or about 10%, on Dec. 18, 2019, wiping out over $1 billion in market capitalization.

"We're focused on investors' losses and whether Allakos misrepresented the conditions and results of its ENIGMA Trial," said Reed Kathrein, the Hagens Berman partner leading the investigation.

If you purchased shares of Allakos and suffered significant losses, click here to discuss your legal rights with Hagens Berman.

Whistleblowers: Persons with non-public information regarding Allakos should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email ALLK@hbsslaw.com.

# # #

About Hagens Berman
Hagens Berman is a national law firm with nine offices in eight cities around the country and eighty attorneys. The firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the firm and its successes is located at hbsslaw.com. For the latest news visit our newsroom or follow us on Twitter at @classactionlaw.

Reed Kathrein

SOURCE: Hagens Berman Sobol Shapiro LLP

View source version on accesswire.com: